San Francisco-based Cytovale® has raised $84 million in Series C funding led by Norwest Venture Partners, with participation from new investors Sands Capital and Global Health Investment Corporation (GHIC), to bring its recently FDA-cleared rapid sepsis diagnostic test – IntelliSep® – to more hospital emergency departments (ED) and health systems in the United States, addressing the historic diagnostic delay that makes sepsis the leading cause of death in U.S. hospitals.

Sepsis is the leading cause of death in US hospitals, accounting for more than one-third of all in-hospital deaths. More common than heart attack and stroke combined in the US, the challenges associated with sepsis are compounded by the lack of a standardized care pathway for evaluating potentially septic patients.

IntelliSep is the first host immune response diagnostic that provides results in less than 10 minutes using standard blood draws and can be seamlessly and efficiently integrated into existing care workflows. IntelliSep takes a unique approach to assessing the body’s immune response to infection by interrogating the morphology and mechanics of immune cells. Put simply, IntelliSep squeezes white blood cells and characterizes their responses – which differ between septic and non-septic patients – using cutting-edge machine learning technology.

With a blood-to-answer time of less than 10 minutes, IntelliSep helps healthcare providers detect sepsis early and make critical, time-sensitive clinical decisions. With the support of our investors, we are now able to expand our efforts to get our tool into the hands of more providers so they can address the potentially fatal outcomes patients currently face,” said Ajay Shah, CEO of Cytovale.

en_GBEnglish (UK)